Corcept Therapeutics Incorporated - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CORT Nasdaq 2834 www.corcept.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Corcept Therapeutics Incorporated

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Jul 17th, 2025 5:10 am
3 Reasons CORT is Risky and 1 Stock to Buy Instead - Jul 16th, 2025 10:08 pm
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Jul 14th, 2025 6:00 am
1 Cash-Producing Stock Worth Your Attention and 2 to Ignore - Jul 6th, 2025 10:33 pm
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - Jul 6th, 2025 2:15 am
Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - Jul 3rd, 2025 11:48 pm
Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Jun 30th, 2025 11:47 am
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Jun 27th, 2025 6:56 am
5 Insightful Analyst Questions From Corcept’s Q1 Earnings Call - Jun 26th, 2025 3:52 pm
Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Jun 24th, 2025 1:09 pm
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care - Jun 23rd, 2025 2:30 pm
June 2025's High Insider Ownership Growth Stocks - Jun 23rd, 2025 5:35 am
Do Its Financials Have Any Role To Play In Driving Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Up Recently? - Jun 23rd, 2025 5:03 am
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Jun 5th, 2025 9:20 am
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - Jun 5th, 2025 4:00 am
2 Profitable Stocks to Target This Week and 1 to Avoid - Jun 4th, 2025 10:31 pm
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? - Jun 4th, 2025 9:30 am
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday - Jun 3rd, 2025 12:59 am
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment - Jun 2nd, 2025 11:24 am
Corcept Therapeutics Says Relacorilant Met Primary Endpoint in Phase 3 Ovarian Cancer Trial - Jun 2nd, 2025 9:45 am